Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study
Niklas Loman(Lund University), Roger Henriksson(Umeå University), Helena Bjermo(Oasmia Pharmaceutical (Sweden)), Elsa Lilienberg(Uppsala University), Nina Heldring(Karolinska University Hospital)
Cited by 33
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Genome-wide association study identifies five susceptibility loci for glioma
|Nature Genetics|2009|797
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
|Cancer Cell|2017|534